BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J, Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clin Res Hepatol Gastroenterol. 2017;41:311-318. [PMID: 28237828 DOI: 10.1016/j.clinre.2016.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31:2035-2052. [PMID: 28692539 DOI: 10.1097/qad.0000000000001574] [Cited by in Crossref: 96] [Cited by in F6Publishing: 49] [Article Influence: 24.0] [Reference Citation Analysis]
2 Rui S, Yan J, Zhang H, Wang Z, Zhou W. Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy. Medicine (Baltimore) 2017;96:e7608. [PMID: 28746212 DOI: 10.1097/MD.0000000000007608] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
4 Li Q, Lu C, Li W, Huang Y, Chen L. Globulin–platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels. Clin Exp Med 2018;18:71-8. [DOI: 10.1007/s10238-017-0472-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
5 Li M, Kong YY, Wu SS, Zhou JL, Wu XN, Wang L, Su JT, Ou XJ, You H, Xie XQ, Wei ZH, Jia JD. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. J Dig Dis 2019;20:467-75. [PMID: 31231938 DOI: 10.1111/1751-2980.12794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Zheng H, Zhang G, Wang F, Yin Z, Miao N, Sun X, Liang X, Cui F. Self-motivated medical care-seeking behaviors and disease progression in a community-based cohort of chronic hepatitis B virus-infected patients in China. BMC Public Health 2019;19:901. [PMID: 31286924 DOI: 10.1186/s12889-019-7061-1] [Reference Citation Analysis]
7 Chen R, Kong W, Gan Y, Ge N, Chen Y, Ding H, Luo J, Wang W, Ren Z. Tumour stiffness associated with tumour response to conventional transarterial chemoembolisation for hepatocellular carcinoma: preliminary findings. Clin Radiol 2019;74:814.e1-7. [PMID: 31421865 DOI: 10.1016/j.crad.2019.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Lu W, Tang H, Yang Z, Jiang K, Chen Y, Lu S. Clinical predictors of small solitary hepatitis B virus-related hepatocellular carcinoma microinvasion. ANZ J Surg 2019;89:E438-42. [PMID: 31508888 DOI: 10.1111/ans.15403] [Reference Citation Analysis]
9 Lu WP, Tang HW, Yang ZY, Jiang K, Chen YL, Lu SC. A proposed modification for the Barcelona Clinic Liver Cancer staging system: Adding bile duct tumor thrombus status in patients with hepatocellular carcinoma. Am J Surg 2020;220:965-71. [PMID: 32336518 DOI: 10.1016/j.amjsurg.2020.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Wu S, Kong Y, Piao H, Jiang W, Xie W, Chen Y, Lu L, Ma A, Xie S, Ding H, Shang J, Zhang X, Feng B, Han T, Xu X, Huo L, Cheng J, Li H, Wu X, Zhou J, Sun Y, Ou X, Zhang H, You H, Jia J. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. Liver Int 2018;38:1045-54. [DOI: 10.1111/liv.13623] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
11 Zhang Z, Shen S. Combined low miRNA-29s is an independent risk factor in predicting prognosis of patients with hepatocellular carcinoma after hepatectomy: A Chinese population-based study. Medicine (Baltimore) 2017;96:e8795. [PMID: 29310356 DOI: 10.1097/MD.0000000000008795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rivera AS, Machenry S, Okpokwu J, Olatunde B, Ugoagwu P, Auwal M, Sule H, Agaba P, Agbaji OO, Thio CL, Murphy RL, Hawkins C. HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria. Antiviral Therapy 2021;26:106-16. [DOI: 10.1177/13596535211058262] [Reference Citation Analysis]